National Health (April 2020 First New Brand statutory price reduction) (Exercise of Ministerial discretion) Determination 2020

Overview

The National Health (April 2020 First New Brand Statutory Price Reduction) (Exercise of Ministerial Discretion) Determination 2020, enacted in 2020, was introduced to exercise specific discretions under the National Health Act 1953. This determination was made by Thea Daniel, the Assistant Secretary of the Pricing and PBS Policy Branch, Technology Assessment and Access Division within the Department of Health, acting as a delegate of the Minister for Health. The objective of this determination is to specify certain brands of pharmaceutical items whose approved ex-manufacturer prices will not undergo the statutory price reduction, as outlined in the Act. This ensures that particular medications retain their original pricing as per the Act's provisions, addressing a specific need identified by the Minister for Health to manage pharmaceutical pricing effectively.

Scope and Application

The National Health (April 2020 First New Brand statutory price reduction) (Exercise of Ministerial discretion) Determination 2020 applies to the pharmaceutical industry, specifically to the pricing of pharmaceutical items listed in the Schedule of the Determination. It is made under subsection 99ACF(3AA) of the National Health Act 1953 and is relevant to the approved ex-manufacturer prices of specific pharmaceutical brands that are not subject to a statutory price reduction as of 1 April 2020. This determination is applicable nationally, given its basis under the Commonwealth Act, impacting the pricing strategies and reimbursements for pharmaceutical products within Australia. The Determination does not specify exclusions or exemptions beyond the brands listed in Schedule 1, which includes certain formulations of Levodopa with carbidopa. The scope of this Determination is limited to the reduction percentage for specified pharmaceutical items, and it does not extend to other pharmaceutical products not listed in the Schedule.

Key Provisions

The main operative sections of the National Health (April 2020 First New Brand statutory price reduction) (Exercise of Ministerial discretion) Determination 2020 (the Determination) include the Authority, Brand of pharmaceutical item not subject to a price reduction, and the Schedule. Section 4 of the Determination indicates that it is made under subsection 99ACF(3AA) of the National Health Act 1953. Section 5 specifies that certain brands of pharmaceutical items are not subject to a price reduction. The Schedule lists the specific pharmaceutical items that are not subject to a price reduction. The Determination imposes obligations and requirements on the parties or entities it governs, primarily by determining that certain brands of pharmaceutical items are not subject to a price reduction for the purposes of subsection 99ACF(2AB) of the Act. The Determination identifies the pharmaceutical items in question and specifies that a reduction of zero percent is to be applied for these items. The Schedule provides a clear and detailed list of the pharmaceutical items that are subject to this condition. There are no explicit offences, penalties, or civil/criminal consequences stated within the Determination for breach of its provisions. However, any breach of the National Health Act 1953, of which this Determination forms a part, could result in penalties as outlined in the Act. These may include fines, imprisonment, or other penalties as determined by a court. The specific penalties would depend on the nature and severity of the breach, as well as any other relevant factors.